Since the lung is a complete black box to even expert physicians, mechanical ventilation (MV) is a rare skill founded on experience and educated guesses. Good MV must become easier and reproducible anywhere. Ebenbuild solves this problem. Their first of a kind simulation/AI software hybrid generates unprecedented data on the patient’s lungs, enabling doctors to provide better-personalized therapy for Acute Respiratory Distress Syndrome (ARDS) and improving the patients’ odds of survival and recovery.
By computing regional distributions of mechanical quantities like stresses and strains, Ebenbuild is effectively offering a novel, computational imaging technique, which makes ventilation therapy quantifiable for the first time. On top of this, they build a comprehensive decision support layer. The scalable software solution can be deployed worldwide regardless of ventilator brand or make and offers benefits for all relevant healthcare stakeholders.
The company participated in our EIT Health Catapult programme in 2021. They applied to the programme with the hope that it will provide them with the opportunity to broaden their network of European digital health experts as well investors that help them to bring their vision to life. Out of the 42 mature start-ups who have entered the semifinals of the programme in December, Ebenbuild managed to secure a spot at the finals on 24 and 25 May.
Now the current investment is a very big step for the whole team at Ebenbuild as the funding will enable them to expand their team and keep on working towards the goal to bring their digital twin technology to patients worldwide.
Congratulations on the investment and we wish you the best of luck at the EIT Health Catapult finals in May!